A review of the JR blood group system

Immunohematology

Volumn 29, Issue 2, 2013, Pages 63-68

  Castilho, Lilian ^a   Reid, Marion E ^b  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b NEW YORK BLOOD CENTER   (United States)

Author keywords

ABCG2; BCRP; Blood groups; JR; Jra antigen

Indexed keywords

ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; ALLOANTIBODY; BLOOD GROUP ANTIGEN; TUMOR PROTEIN;

ALLELE; BLOOD; CHROMOSOME 4; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; NEWBORN HEMOLYTIC DISEASE;

ALLELES; ATP-BINDING CASSETTE TRANSPORTERS; BLOOD GROUP ANTIGENS; CHROMOSOMES, HUMAN, PAIR 4; ERYTHROBLASTOSIS, FETAL; HUMANS; ISOANTIBODIES; NEOPLASM PROTEINS;

EID: 84891524170     PISSN: 0894203X     EISSN: 19303955     Source Type: Journal    
DOI: 10.21307/IMMUNOHEMATOLOGY-2019-126     Document Type: Review

References (62)

1. Stroup M, MacIlroy M Jr. Five examples of an antibody defining an antigen of high frequency in the Caucasian population (conference abstract). 23rd Annual Meeting of the American Association of Blood Banks, San Francisco, CA; 1970:86.
2. Gellerman M, Stroup M. Unpublished observations, cited in Race RR, Sanger R. Blood groups in man. 6th ed., pp. 441-424 (Blackwell, Oxford 1975).
3. Miyazaki T, Kwon KW, Yamamoto K, et al. A human monoclonal antibody to high frequency red cell antigen Jra. Vox Sang 1994;66:51-4.
4. Nakajima H, Ito K. An example of anti-Jra causing hemolytic disease of the newborn and frequency of Jra antigen in the Japanese population. Vox Sang 1978;35:265-7.
5. Okubo Y. Some rare blood group phenotypes in Japanese, Fy(a-), Di(b-) and Jr(a-) (in Japanese). Blood Programme 1978;1:279-84.
6. Tritchler JE. An example of anti-Jra. Transfusion 1977;17: 177-8.
7. Kendal AG. Clinical importance of the rare erythrocyte antibody anti-Jra. Transfusion 1976;16:646-7.
8. Levene C, Sela R, Dvilansky A, Yermiahu T, Daniels G. The Jr(a-) phenotype and anti-Jra in two Beduin Arab women in Israel. Transfusion 1986;26:119-20.
9. VedoM,ReidME.Anti-JrainaMexicanAmerican.Transfusion 1978;18:569.
10. Yamaguchi H, Okubo Y, Seno T, et al. A rare phenotype blood Jr(a-) occurring in two successive generations of a Japanese family. Proc Jpn Acad 1976;52:521-3.
11. Orrick LR, Golde SH. Jra mediated hemolytic disease of the newborn infant. Am J Obstet Gynecol 1980;137:135-6.
12. Toy P, Reid M, Lewis T, Ellisor S, Avoy DR. Does anti-Jra cause hemolytic disease of the newborn? Vox Sang 1981;41:40-4.
13. Bacon J, Sherrin D, Wright RG. Case report, anti-Jra (letter). Transfusion 1986;26:543-4.
14. Bellver-Pradas J, Arriaga-Chafer F, Perales-Marin A, Maisques-Montesinos V, Serra-Serra V. Obstetric significance of anti-Jra. Am J Obstet Gynecol 2001;184:75-6.
15. Ishihara Y, Miyata S, Chiba Y, Kawai T. Successful treatment of extremely severe fetal anemia due to anti-Jra alloimmunization. Fetal Diagn Ther 2006;21:269-71.
16. Peyrard T, Pham BN, Arnaud L, et al. Obstetric significance of anti-Jra: study of twenty pregnancy outcomes showing three cases of severe hemolytic disease of the fetus and newborn (abstract). Transfusion 2008;48(Suppl):14A.
17. Peyrard T, Pham BN, Arnaud L, et al. Fatal hemolytic disease of the fetus and newborn associated with anti-Jra. Transfusion 2008;48:1906-11.
18. Arriaga F, Gomez I, Lineares MD, Gascon A, Carpio N, Perales A. Fatal hemolytic disease of the fetus and newborn possibly due to anti-Jra (letter). Transfusion 2009;49:813.
19. Masumoto A, Masuyama H, Sumida Y, Segawa T, Hiramatsu Y. Successful management of anti-Jra alloimmunization in pregnancy: a case report. Gynecol Obstet Invest 2010;69:81-3.
20. Kim H, Park M-J, Sung T-J, et al. Hemolytic disease of the newborn associated with anti-Jra alloimmunization in a twin pregnancy: the first case report in Korea. Korean J Lab Med 2010;30:511-15.
21. Sasamoto N, Tomimatsu T, Nagamine K, et al. Fetal and neonatal anemia associated with anti-Jra: a case report showing a poorly hemolytic mechanism. J. Obstet Gynaecol Res 2011;37:1132-6.
22. Verska JJ, Larson NL. Autologous transfusion in cardiac surgery: a case report of a patient with a rare antibody. Transfusion 1973;13:219-20.
23. Yoshida H, Yurugi K, Ito K. A case of delayed hemolytic transfusion reaction due to anti-Jra. Jpn J Tranfus Med 1991; 34:528-30.
24. Jowitt S, Powell H, Shwe KH, Love EM. Transfusion reaction due to anti-Jra. (abstract). Transfusion Med 1994;4(Suppl 1):49.
25. Pisacka M, Prosicka M, Kralova M, et al. Six cases of anti-Jra antibody detected in one year: a probable relation with Gypsy ethnic minority from central Slovakia. (abstract). Vox Sang 2000;78(suppl):P146.
26. Yuan S, Armour R, Reid A, et al. Case report: massive postpartum transfusion of Jr(a+) red cells in the presence of anti-Jra. Immunohematology 2005;21:97-101.
27. Kwon MY, Su L, Arndt P, Garratty G, Blackall DP. Clinical significance of anti-Jra: report of two cases and review of the literature. Transfusion 2004;44:197-201.
28. Hundric Haspl HH, Jurakovic Loncar JL, et al. The clinical significance of anti-Jra: mild or severe? (abstract). Vox Sang 2007;93(Suppl 1):208-9.
29. Lewis M, Anstee DJ, Bird GWG, et al. Blood group terminology 1990. The ISBT Working Party on Terminology for Red Cell Surface Antigens. Vox Sang 1990;58:152-69.
30. Zelinski T, Coghlan G, Liu XG, Reid ME. ABCG2 null alleles define the Jr(a-) blood group phenotype. Nat Genet 2012;44:131-2.
31. Saison C, Helias V, Balif BA, et al. Null alleles of ABCG2 encoding the breast cancer resistance protein define the new blood group system Junior. Nat Genet 2012;44:174-7.
32. Hue-Roye K, Lomas-Francis C, Coghlan G, Zelinski T, Reid ME. The JR blood group system (ISBT 032): molecular characterization of three new alleles. Transfusion 2012 Oct 15. [Epub ahead of print].
33. Hue-Roye K, Zelinski T, Cobaugh A, Lomas-Francis C, Miyazaki T, Reid ME. The JR blood group system: alleles that alter expression? (abstract). Transfusion 2013 Feb 25. [Epub ahead of print].
34. Imai Y, Nakane M, Kage K, et al. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 2002;1:611-16.
35. Kobayashi D, Ieiri I, Hirota T, et al. Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab Dispos 2005;33:94-101.
36. Bailey-Dell KJ, Hassel B, Doyle LA, Ross DD. Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene. Biochim Biophys Acta 2001;1520:234-41.
37. Klein I, Sarkadi B, Váradi A. An inventory of the human ABC proteins. Biochim Biophys Acta 1999;1461:237-62.
38. Woodward OM, Köttgen A, Köttgen M. ABCG transporters and disease. FEBS J 2011;278:3215-25.
39. Leimanis ML, Georges E. ABCG2 membrane transporter in mature human erythrocytes is exclusively homodimer. Biochem Biophys Res Commun 2007;354:345-50.
40. Xu J, Liu Y, Yang Y, Bates S, Zhang JT. Characterization of oligomeric human half-ABC transporter ATP-binding cassette G2. J Biol Chem 2004;279:19781-9.
41. Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998;95:15665-70.
42. Maliepaard M, Scheffer GL, Faneyte IF, et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 2001;61:3458-64.
43. Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, Dean M. A human placenta-specific ATP binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 1998;58:5337-9.
44. Miyake K, Mickley L, Litman T, et al. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res 1999;59:8-13.
45. Woodward OM, Köttgen A, Coresh J, Boerwinkle E, Guggino WB, Köttgen M. Identification of urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc Natl Acad Sci U S A 2009;106:10338-42.
46. Wielinga P, Hooijberg JH, Gunnarsdottir S, et al. The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates. Cancer Res 2005;65:4425-30.
47. Krishnamurthy P, Xie T, Schuetz JD. The role of transporters in cellular heme and porphyrin homeostasis. Pharmacol Ther 2007;114:345-58.
48. Tamura A, Masato W, Saito H, et al. Functional validation of the genetic polymorphisms of human ATP-binding cassette (ABC) transporter ABCG2: identification of alleles that are defective in porphyrin transport. Mol Pharmacol 2006;70:287-96.
49. Huls M, Russel FG, Masereeuw R. The role of ATP binding cassette transporters in tissue defense and organ regeneration. J Pharmacol Exp Ther 2009;328:3-9.
50. Kusuhara H, Sugiyama Y. Active efflux across the blood-brain barrier: role of the solute carrier family. NeuroRx 2005;2: 73-85.
51. Dauchy S, Dutheil F, Weaver RJ, et al. ABC transporters, cytochromes P450 and their main transcription factors: expression at the human blood-brain barrier. J Neurochem 2008;107:1518-28.
52. Borst P, Elferink O. Mammalian ABC transporters in health and disease. Annu Rev Biochem 2002;71:537-92.
53. Doyle L, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003;22:7340-58.
54. Natarajan K, Xie Y, Baer MR, Ross DD. Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. Biochem Pharmacol 2012;83:1084-103.
55. Matsuo H, Takada T, Ichida K, et al. Common defects of ABCG2, a high-capacity urate transporter, cause gout: a function-based genetic analysis in a Japanese population. Sci Transl Med 2009;1:5ra11.
56. Tiribelli M, Fabbro D, Franzoni A, Fanin R, Damante G, Damiani D. Q141K polymorphism of ABCG2 protein is associated with poor prognosis in adult acute myeloid leukemia treated with idarubicin-based chemotherapy. Haematologica 2012 Oct 12. [Epub ahead of print].
57. Reid ME, Lomas-Francis C, Olsson ML. The blood group antigen factsbook. 3rd ed. San Diego, CA: Elsevier; 2012.
58. Takeshita A, Watanabe H, Fijihara H, et al. Collaborative study of irregular erythrocyte antibodies in Japan: results from the Japanese study group of allo-immunity and antigen diversity in Asian populations. Transf Apher Sci 2010;43:3-8.
59. Ogasawara K, Mazuda T. Characterization of Jra antibodies by monocyte phagocytosis assays and flow cytometry analysis (in Japanese). Acta Haematol Jpn 1990;53:1131-7.
60. Garratty G, Arndt P, Nance S. The potential clinical significance of blood group alloantibodies to high frequency antigens (abstract). Blood 1997;10(Suppl 1):473a.
61. Vaughan JI, Warwick R, Letsky E, Nicolini U, Rodeck CH, Fisk NM. Erythropoietic suppression in fetal anemia because of Kell alloimmunization. Am J Obstet Gynecol 1994;171:247-52.
62. Arndt PA, Garratty G, Daniels G, et al. Late onset neonatal anaemia due to maternal anti-Ge: possible association with destruction of erythroid progenitors. Transfus Med 2005;15:125-32.